Literature DB >> 24871455

Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease.

Leslie R Cockerham1, Vivek Jain, Elizabeth Sinclair, David V Glidden, Wendy Hartogenesis, Hiroyu Hatano, Peter W Hunt, Jeffrey N Martin, Christopher D Pilcher, Rafick Sekaly, Joseph M McCune, Frederick M Hecht, Steven G Deeks.   

Abstract

BACKGROUND: There is intense interest in the role of programmed death 1 (PD-1) in causing persistent T-cell dysfunction in HIV infection. However, the impact of HIV infection and antiretroviral treatment (ART) on the expression of PD-1 on T cells is still poorly defined.
METHODS: PD-1 was measured longitudinally in a cohort of recently HIV-infected individuals (n = 121) who started ART early (<6 months after infection) vs. later (≥2 years after infection). PD-1 was also measured cross-sectionally in a diverse cohort of chronically HIV-infected adults (n = 206).
RESULTS: PD-1 expression levels were high on CD8⁺ T cells during early HIV infection. PD-1 levels increased on both CD4⁺ and CD8⁺ T cells populations in those who delayed therapy (11 and 10%/year, respectively). PD-1 levels declined and were similar in those treated early vs. late after 1 year of ART. In both cohorts, PD-1 expression on CD4⁺ T cells was associated with CD4⁺ T-cell activation (CD38⁺HLA-DR⁺) and inversely with CD4⁺ cell count. In contrast, PD-1 expression on CD8⁺ T cells was most strongly associated with CD8⁺ T-cell activation and with plasma viral load in viremic individuals.
CONCLUSION: Across two large cohorts of untreated and treated individuals, we found consistent associations between HIV RNA levels, CD8⁺ T-cell activation and PD-1 expression on CD8⁺ T cells. In contrast, CD4⁺ T-cell counts and CD4⁺ T-cell activation were more consistent correlates of PD-1 expression on CD4⁺ T cells. PD-1 expression appears to be driven by both direct antigen and homeostatic pathways.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24871455      PMCID: PMC4206412          DOI: 10.1097/QAD.0000000000000314

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis.

Authors:  L A Napolitano; R M Grant; S G Deeks; D Schmidt; S C De Rosa; L A Herzenberg; B G Herndier; J Andersson; J M McCune
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

2.  HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.

Authors:  Marta Catalfamo; Michele Di Mascio; Zonghui Hu; Sharat Srinivasula; Vishakha Thaker; Joseph Adelsberger; Adam Rupert; Michael Baseler; Yutaka Tagaya; Gregg Roby; Catherine Rehm; Dean Follmann; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-05       Impact factor: 11.205

3.  Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.

Authors:  Stefania Piconi; Daria Trabattoni; Andrea Gori; Serena Parisotto; Carlo Magni; Paola Meraviglia; Alessandra Bandera; Amedeo Capetti; Giuliano Rizzardini; Mario Clerici
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

4.  Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

Authors:  Rebecca K Lodwick; Caroline A Sabin; Kholoud Porter; Bruno Ledergerber; Ard van Sighem; Alessandro Cozzi-Lepri; Pavel Khaykin; Amanda Mocroft; Lisa Jacobson; Stephane De Wit; Niels Obel; Antonella Castagna; Jan-Christian Wasmuth; John Gill; Marina B Klein; Stephen Gange; Melchor Riera; Cristina Mussini; Félix Gutiérrez; Giota Touloumi; Patrizia Carrieri; Jodie L Guest; Norbert H Brockmeyer; Andrew N Phillips
Journal:  Lancet       Date:  2010-07-15       Impact factor: 79.321

5.  Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease.

Authors:  David M Naeger; Jeffrey N Martin; Elizabeth Sinclair; Peter W Hunt; David R Bangsberg; Frederick Hecht; Priscilla Hsue; Joseph M McCune; Steven G Deeks
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

6.  PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status.

Authors:  Delphine Sauce; Jorge R Almeida; Martin Larsen; Laurine Haro; Brigitte Autran; Gordon J Freeman; Victor Appay
Journal:  AIDS       Date:  2007-10-01       Impact factor: 4.177

7.  Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era.

Authors:  Leslie Cockerham; Rebecca Scherzer; Andrew Zolopa; David Rimland; Cora E Lewis; Peter Bacchetti; Carl Grunfeld; Michael Shlipak; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit.

Authors:  Praveen K Amancha; Jung Joo Hong; Kenneth Rogers; Aftab A Ansari; Francois Villinger
Journal:  J Immunol       Date:  2013-11-13       Impact factor: 5.422

10.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

View more
  56 in total

1.  Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

Authors:  Sharon Lam; Julia Sung; Conrad Cruz; Paul Castillo-Caro; Minhtran Ngo; Carolina Garrido; Joann Kuruc; Nancie Archin; Cliona Rooney; David Margolis; Catherine Bollard
Journal:  Mol Ther       Date:  2014-11-04       Impact factor: 11.454

2.  Programmed cell death-1 single-nucleotide polymorphism rs10204525 is associated with human immunodeficiency virus type 1 RNA viral load in HIV-1-infected Moroccan subjects.

Authors:  Hanâ Baba; Anass Kettani; Meryem Bouqdayr; Ahd Ouladlahsen; Rajaa Bensghir; Latifa Marih; Mustapha Sodqi; Soumaya Benjelloun; Sayeh Ezzikouri; Imane Zaidane; Fatima-Zahra Jadid; Kamal Marhoum El Filali; Lahcen Wakrim
Journal:  Med Microbiol Immunol       Date:  2021-05-24       Impact factor: 3.402

3.  Predict disease progression from T-cell phenotypes in northern pig-tailed macaques (Macaca leonina) during SIVmac239 infection.

Authors:  Ming-Xu Zhang; Hong-Yi Zheng; Jin Jiang; Jia-Hao Song; Min Chen; Yu Xiao; Xiao-Dong Lian; Tian-Zhang Song; Ren-Rong Tian; Wei Pang; Yong-Tang Zheng
Journal:  Immunology       Date:  2017-08-14       Impact factor: 7.397

4.  Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression.

Authors:  Rachel Lena Rutishauser; Wendy Hartogensis; Christian Deo Deguit; Melissa Krone; Rebecca Hoh; Frederick M Hecht; Christopher D Pilcher; Peter Bacchetti; Steven G Deeks; Peter W Hunt; Joseph M McCune
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-25       Impact factor: 2.205

5.  Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV.

Authors:  Geetha H Mylvaganam; Lynette S Chea; Gregory K Tharp; Sakeenah Hicks; Vijayakumar Velu; Smita S Iyer; Claire Deleage; Jacob D Estes; Steven E Bosinger; Gordon J Freeman; Rafi Ahmed; Rama R Amara
Journal:  JCI Insight       Date:  2018-09-20

6.  Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs Lie.

Authors:  Kellie N Smith; Robbie B Mailliard; Charles R Rinaldo
Journal:  For Immunopathol Dis Therap       Date:  2015

Review 7.  The Sordid Affair Between Human Herpesvirus and HIV.

Authors:  Sara Gianella; Marta Massanella; Joel O Wertheim; Davey M Smith
Journal:  J Infect Dis       Date:  2015-03-06       Impact factor: 5.226

8.  Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.

Authors:  Lesley R de Armas; Suresh Pallikkuth; Stefano Rinaldi; Rajendra Pahwa; Savita Pahwa
Journal:  AIDS Res Hum Retroviruses       Date:  2019 Nov/Dec       Impact factor: 2.205

Review 9.  Residual inflammation and viral reservoirs: alliance against an HIV cure.

Authors:  Marta Massanella; Rémi Fromentin; Nicolas Chomont
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

10.  Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Authors:  Ping Chen; Hui Chen; Maha Moussa; Jie Cheng; Tong Li; Jing Qin; Jeffrey D Lifson; Michael C Sneller; Ludmila Krymskaya; Steven Godin; H Clifford Lane; Marta Catalfamo
Journal:  J Infect Dis       Date:  2020-02-03       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.